On October 1, 2021 Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, reported it will present four posters at SITC (Free SITC Whitepaper)’s 36th Annual Meeting being held Wednesday, November 10, 2021 to Sunday, November 14, 2021 (Press release, Shattuck Labs, OCT 1, 2021, View Source [SID1234591769]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Abstract Title: Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint SL-172154 (SIRPα-Fc-CD40L) in Subjects with Platinum-resistant Ovarian Cancer
Abstract Number: 429
Presenter: Nehal J. Lakhani, MD, PhD, START Midwest
Date: November 12th – 14th
Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET
Abstract Title: Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint (ARC) Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects with Advanced Solid Tumors or Lymphomas
Abstract Number: 494
Presenter: Melissa Johnson, MD, Sarah Cannon Research Institute
Date: November 12th – 14th
Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET
Abstract Title: Development of an Integrated Method to Quantify Receptor Occupancy for Agonist Immunotherapeutics That Stimulate Target Cells to Migrate from the Peripheral Blood
Abstract Number: 3
Presenter: Louis Gonzalez, PhD, Shattuck’s Director of Translational Research
Date: November 12th – 14th
Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET
Abstract Title: LIGHT (TNFSF14) Co-stimulation Enhances Myeloid Cell Activation and Anti-tumor Immunity in the Setting of PD-1 and TIGIT Checkpoint Blockade
Abstract Number: 585
Presenter: George Fromm, PhD, Shattuck’s Vice President of Research & Development
Date: November 12th – 14th
Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET
Further information about the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Meeting can be found at:
View Source